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Background: The impact of smoking at diagnosis and subsequent smoking cessation on clinical 34 
outcomes in Crohn's disease (CD)has not been evaluated in a population based cohort. 35 
Methods: Using a nationally representative clinical research database, we identified incident cases 36 
of CD between 2005 and 2014. We compared the following outcomes: overall corticosteroid (CS) 37 
use; flares requiring CS;  CS-dependency and intestinal surgery between smokers and non-smokers 38 
at time of CD diagnosis. Differences in these outcomes were also compared between persistent 39 
smokers and smokers who quit within 2 years of  diagnosis. 40 
Results: We identified 3553 patients with a new CD diagnosis over the study period of whom 1121 41 
(32%) were smokers. Smokers at CD diagnosis had significantly higher CS-use (56% vs. 47%, 42 
p<0.0001), proportionally more CS-flares (>1 CS flare/yr:  9% vs 6%, p<0.0001), and higher CS-43 
dependency (27% vs. 21%, p<0.0001) than non-smokers. Regression analysis identified smoking at 44 
diagnosis to be associated with a higher risk of intestinal surgery (HR 1.64, 95%CI 1.16-2.52). There 45 
was a significantly higher proportion of 'quitters' who remained steroid-free through follow-up in 46 
comparison to 'persistent smokers' (45.4% vs. 37.5% respectively, p=0.02). 'Quitters' also had lower 47 
rates of CS-dependency compared to 'persistent smokers' (24% vs 33%, p=0.008). 48 
Conclusions: Smokers at CD diagnosis have higher CS-use, CS-dependency and higher risk of 49 
intestinal surgery. Quitting smoking appears to have beneficial effects on disease related outcomes 50 
including reducing CS-dependency highlighting the importance of offering early  smoking cessation 51 
support. 52 
  53 
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Study highlights 54 
1) What is current knowledge: 55 
 smoking is common amongst patients with Crohn's disease (CD) 56 
 smoking may worsen outcomes in CD but the exact association remains unclear, and much 57 
of the available data comes from secondary and tertiary care centres 58 
 there is only limited data on the impact of smoking cessation in outcomes in CD 59 
2) What is new here: 60 
 patients with CD who are smokers at the time of diagnosis have higher overall corticosteroid 61 
(CS) use compared to non-smokers 62 
 CS dependency, as defined by international guidelines, is more frequent  amongst CD 63 
patients  who smoke at diagnosis 64 
 patients with CD who smoke at diagnosis are two thirds more likely to undergo intestinal 65 
surgery 66 
 patients with CD who stop smoking within the first two years of diagnosis have lower rates 67 
of CS dependency and are more likely to be steroid-free 68 




Smoking is a key modifiable environmental risk factor implicated in the onset of Crohn's disease 71 
(CD).1 Despite recent global reductions, approximately one in five British adults smoke currently.2  72 
Recent data from the UK indicates there may be a similar prevalence amongst patients with CD,3 73 
although in some CD populations smoking is much more frequent.4,5  74 
Tobacco exposure impacts adversely on disease outcomes in CD. Several studies have reported 75 
increased rates of intestinal surgery amongst smokers.6,7,8,9 Smoking may also impact upon other 76 
clinically important indices including disease flares, corticosteroid requirement and immuno-77 
modulator use,10,11,12 although a few small studies have found no association between tobacco 78 
exposure and poorer outcomes.13,14,15 79 
The majority of previous studies examining the relationship between smoking and disease outcomes 80 
in CD have originated from secondary or tertiary care and are therefore likely to comprise of patients 81 
with a more severe phenotype. In a recent meta-analysis on the impact of smoking on disease 82 
outcomes in CD thirty-two of the 33 studies were derived from referral centres.16 Population-based 83 
studies reporting on the relationship between smoking and disease course in CD are fewer in 84 
number,3,13 yet may be better placed to examine the true impact of smoking on outcomes in CD as 85 
they will include a more diverse range of patient phenotypes.  86 
Despite strong evidence that smoking is detrimental to gut health in CD, there is limited evidence 87 
that smoking cessation can improve disease outcomes.17,18 To our knowledge, the potential benefits 88 
of smoking cessation have not previously been evaluated in a population based cohort that is free of 89 
referral centre bias. 90 
We therefore aimed  to perform a population based study to investigate both the impact of smoking 91 
status at diagnosis and the impact of subsequent smoking cessation after diagnosis on clinical 92 
outcomes in Crohn’s disease. We hypothesised that smoking at the time of CD diagnosis is an 93 
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independent risk factor associated with adverse outcomes in CD and that smoking cessation would 94 
impact favourably. 95 
 96 




Data source 99 
We created a retrospective population-based incident cohort of all patients diagnosed with Crohn’s 100 
disease using the Clinical Practice Research Datalink (CPRD). CPRD is one of the largest and best 101 
validated primary care research databases in the world. Importantly, it is not an administrative 102 
dataset and thus is free from the biases inherent of such data sources. It contains longitudinal, 103 
patient-level, anonymised electronic health records from 674 general practices and is representative 104 
of around 8% of the United Kingdom (UK) population.19 Primary care physicians use Read codes to 105 
record symptoms, signs, diagnoses, prescriptions, referrals and procedures including surgical 106 
operations. Data are rigorously audited to ensure a high level of accuracy and completeness. 107 
Participating practices need to achieve and maintain 'Up to standard' (UTS) status to continue 108 
contributing to the dataset. The database's primary purpose is for epidemiological research and the 109 
coding system has been previously validated for use in IBD.20 Numerous IBD related studies have 110 
been undertaken using this data source.21,22,23,24 Furthermore, the CPRD has been used in a number 111 
of population based studies investigating both smoking habits and the impact of tobacco 112 
consumption on outcomes in other patient populations.25,26,27 CPRD is well suited for this purpose 113 
and subsequent accuracy of recording of smoking status has been of high quality since its 114 
assessment became a key performance indicator for GPs in 2004.28  115 
We obtained ethical and scientific approval for the use of CPRD for our study from the Independent 116 
Scientific Advisory Committee (ISAC Protocol number: 15_018R). 117 
Incident case definition and cohort construction 118 
We have previously published detailed methodologies in defining incident cases of inflammatory 119 
bowel disease from the CPRD.29,30,31,32,33 In brief, to separate prevalent from incident cases of CD, we 120 
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identified patients with a first Read code for CD at least one year after registering with a 'Up To 121 
Standard' practice for the period January 1st 2005 to December 31st 2014. 122 
Patients were excluded if they had Read codes for both ulcerative colitis and CD, or indeterminate 123 
codes ('non-specific colitis', 'colitis NOS' etc). Patients who had a co-morbid condition that might 124 
require regular or prolonged steroid use, for example, chronic asthma or polymyalgia rheumatica 125 
patients, were also excluded to avoid potential confounding. Patients with previous organ 126 
transplants were also excluded because of the likely use of concurrent immunosuppressant and 127 
steroid medications in this group. Patients were followed up from date of CD diagnosis until study 128 
endpoint, de-registration, or death. 129 
Exposure variable 130 
Our main exposure variable was smoking status at CD diagnosis. Patients were defined as either  131 
'smokers' or 'non-smokers' at the time of CD diagnosis based on Read codes for smoking status in 132 
the year before the first recorded CD diagnosis. 'Non-smokers' at CD diagnosis included patients who 133 
were either ex-smokers of at least one year, or 'never smokers', as defined by Read codes (see 134 
additional online material). Where patients had contradicting or multiple codes for smoking status in 135 
the preceding year, the smoking code closest to the date of CD diagnosis was used. Completeness of 136 
smoking data within our dataset was approximately 80% (Figure 1). Accuracy of smoking status 137 
recording in CPRD has been demonstrated to be within 1% of self-reported smoking habits in 138 
national surveys.34 Since April 2004, financial incentives in primary care were introduced for GPs to 139 
offer smoking cessation advice to patients aged over 16 years via the UK Quality and Outcomes 140 
Framework (QOF) scheme. This has substantially increased completeness of recording  of smoking 141 
status.28 We therefore chose a start for the study of January 1st 2005, 9 months after 142 
implementation of this scheme. 143 
For the secondary analysis, we identified patients with further Read codes for smoking status in the 144 
first two years after CD diagnosis. Patients were considered 'persistent smokers' if they were 145 
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smokers at CD diagnosis (as defined above) and had at least one further Read code indicating a 146 
smoking status within 2 years after diagnosis. Patients were labelled as 'quitters' if they were 147 
smokers at CD diagnosis, but had at least one subsequent Read code indicating they were non-148 
smokers or ex-smokers in the two years following CD diagnosis. 149 
Outcome measures 150 
Our primary outcome measure was oral corticosteroid (CS) use as a proxy measure of a CS-requiring 151 
disease flare-up ('CS-flare') indicative of an exacerbation of CD. We derived 3 measures of CS use. 152 
Firstly we calculated the proportion of patients 'ever exposed' or 'never exposed' to oral CS. Patients 153 
were identified as 'ever exposed' if they had at least one prescription for oral CS during follow-up.   154 
Secondly, we used a previously published methodology described by Grainge et al. to define the 155 
number of 'CS flares' during follow up.35 The first 'CS-flare' was defined as the first CS prescription 156 
registered in the patient record after date of CD diagnosis. The next separate 'CS-flare' was defined 157 
where a subsequent CS prescription was recorded following a period of at least 4 months without a 158 
CS prescription. This methodology allowed for the determination of total 'CS-flares' for the entire 159 
period of follow-up for each patient. Thus, the total number of 'CS-flares' was divided by follow-up 160 
time to generate the outcome measure 'CS-flares per year'. 161 
Thirdly, we identified patients with steroid-dependency (defined as prolonged or repeated CS 162 
exposure) adapted from the European Crohn's and Colitis Organisation guidelines criteria.36 A 163 
patient was defined as 'CS-dependent' if they had either a prescription for CS that lasted longer than 164 
3 months, or required a repeat CS prescription within 3 months of stopping the previous CS course. 165 
CS-dependency has been shown to be associated with poorer outcomes in patients with CD.37 166 
Our secondary outcome measure was first intestinal surgery. This was defined as the first intestinal 167 
surgical procedure coded for following diagnosis of CD, and was derived using Read/OXMIS codes for 168 




We included a number of covariates with known or likely associations with poorer clinical outcomes 171 
in CD.  These included: age at diagnosis, body mass index, social deprivation, severity of CD, 172 
concurrent 5-aminosalicylic acid (5ASA) or thiopurine use, and co-morbid conditions. Age at 173 
diagnosis has previously been shown to be relevant to surgical outcomes in the context of smoking 174 
status.3  Patients were sub-divided into age categories at diagnosis of CD according to the Montreal 175 
Classification (A1 - age less than 17 years, A2 - 17 years to 40 years, A3 - age greater than 40 at initial 176 
CD diagnosis). We also extracted data for Body Mass Index (BMI) at diagnosis, defined as the closest 177 
BMI recording within 1 year of CD diagnosis. Patients were defined as: underweight 178 
(BMI<18.5kg/m2), normal weight (18.5-25kg/m2), overweight (25-30kg/m2) or obese (>30 kg/m2). 179 
BMI may be associated with risk of surgery in CD.38 We used a surrogate marker for postcode-linked 180 
social deprivation, the Index of Multiple Deprivation (IMD) to stratify patients by socio-economic 181 
status. Patients were categorised into IMD quintiles where IMD category 1 represents the least 182 
deprived, and IMD category 5 represents the most socio-economically deprived.  In the UK, people 183 
living in the areas of highest deprivation are more than twice as likely to smoke compared to the 184 
lowest.39 We also identified patients with co-morbid irritable bowel syndrome (IBS) and depression. 185 
IBS is common in patients with IBD and may be confused with the symptoms of an IBD flare.40 186 
Furthermore, smoking is highly correlated with depressive illnesses.41 We defined these co-187 
morbidities to include any patient with a concurrent Read code for either IBS or a depressive 188 
diagnosis during the follow-up period.  189 
We also extracted data for IBD medication usage other than CS. Patients were defined as 5-190 
aminosalicylic acid (5ASA) users if they had one of more prescriptions during follow up. Similarly, 191 
patients were defined as thiopurine (TP) users if they had one or more prescriptions for azathioprine 192 
(AZA) or 6-mercaptopurine (6MP) during follow-up. Prescription data for anti-tumour necrosis factor 193 
(aTNF) use is not reliably recorded in CPRD. 194 
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We classified disease severity using a modification of the Beaugerie Index of severity.42 This is a 195 
validated 4-point score calculated using three clinical variables that predict a 'disabling' disease 196 
course in CD, including a higher risk of IBD medication use, hospitalisation and surgery. The three 197 
variables are: age of CD onset < 40 years, early use of CS, defined in our population as a first CS 198 
prescription within 3 months of CD diagnosis, and lastly the presence of peri-anal disease, defined 199 
for the purpose of this study by codes for peri-anal surgery, as previously described.32 A patient may 200 
have a score between zero (none of the variables) and 3 (all three variables). A score of 2 or more is 201 
associated with a positive predictive value of over 90% for 'disabling' disease.42 202 
The 10 year study period was divided into five 2-year era to allow for assessment of the impact of 203 
era of CD diagnosis on outcome measures (era 1: 1/1/05 to 31/12/06, era 2: 01/1/07 to 31/12/08, 204 
era 3: 01/1/09 to 31/12/10, era 4: 01/1/11 to 31/1/12, era 5: 01/1/13 to 31/12/14). 205 
Statistical analysis 206 
We used t-tests to determine differences between groups of continuous data, and Chi-squared or 207 
Fisher’s exact test for comparisons of categorical data. We compared the proportion of smokers 208 
versus non-smokers at CD diagnosis who had any CS exposure, the number of CS flares per year in 209 
each group, and the proportion of patients with steroid dependency.  210 
We used Kaplan-Meier analysis to generate survival curves calculating the time to first oral CS 211 
prescription in smokers and non-smokers. For both smokers and non-smokers, we calculated 212 
cumulative oral CS exposure rates in the follow-up period. The rate of oral CS exposure was 213 
determined as a function of time, by calculating the duration between diagnosis of CD and first oral 214 
CS prescription, or end of follow-up as defined above. The risk of oral CS use at 1, 3 and 5 years after 215 
CD diagnosis was also calculated. We used the log rank test to assess for any significant differences 216 
between smokers and non-smokers. We used the same statistical methodology to calculate the 1,3 217 
and 5 year risk of first intestinal surgery between smokers and non-smokers. 218 
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In a further analysis, we used separate Cox proportional hazards models to calculate hazard ratios 219 
(HR) for first intestinal surgery given smoking status at CD diagnosis. All available variables included 220 
in the univariate and multivariate analysis. Within this model we adjusted for sex, Montreal age 221 
category, BMI, era of CD diagnosis, IMD status (dichotomous variable - upper two IMD quintiles 222 
versus lower 3 quintiles), co-morbid depression, concurrent IBS, 5ASA and TP use, and disease 223 
severity (Beaugerie index score of greater than or equal to 2).  224 
In the analysis comparing 'quitters' versus 'persistent smokers', we used similar outcome measures 225 
as for the primary analysis. CS flare rate, CS-dependency and IR rates were compared between these 226 
two sub-groups using student's t-test, Chi squared test, and KM survival analysis with the log rank 227 
test. 228 
A p-value of less than or equal to 0.05 was considered statistically significant. All analyses were 229 
performed using STATA 12 (Statacorp LP, College Station, TX, USA). 230 




We identified 3553 patients with a new diagnosis of CD with 14806 person years of follow up 233 
between January 1st 2005 and December 31st 2014 (Figure 1). 1121 of 3553 patients (31.6%) were 234 
smokers at CD diagnosis. The difference in follow-up time between smokers (n=1121) and non 235 
smokers (n=2432) was not significant (4.3 years versus 4.1 years, p=0.22). The overall proportion of 236 
smokers at diagnosis across the 5 era remained constant. However, the proportion of smokers at CD 237 
diagnosis aged 17-40 (Montreal A2 category) dropped from 37.4% in years 2005-6 (era 1) to 30.5% in 238 
years 2013-14 (era 5 - Figure 2).  239 
At baseline, there was no difference in the proportion of smokers and non-smokers aged 17-40 years 240 
(Montreal A2) and aged >40 years (Montreal A3) respectively. There were significantly more non-241 
smokers than smokers in the youngest age cohort (Table 1). 242 
 Amongst patients with CD, smokers were more likely to be female, live in deprived areas, and have 243 
a concurrent diagnosis of depression (Table 1). No differences between smokers and non-smokers 244 
were observed in the other baseline characteristics including BMI at diagnosis, IBS prevalence or 245 
disease severity. Nor were there any significant differences in 5-ASA use (52.1% versus 54.5%) and 246 
thiopurine use (35.5% versus 32.4%) during follow-up between smokers and non-smokers 247 
respectively.  248 
Corticosteroid use 249 
Smokers had more overall exposure to oral CS therapy. Crude oral CS exposure was 55.8% in 250 
smokers versus 47.0% in non-smokers (p<0.0001). Smokers were less likely to have CS-free 251 
remission, defined as no 'CS-flares' in follow-up. Smokers also had significantly more 'CS (requiring) 252 
flares' per year when compared with non-smokers (Table 2). Similarly, a higher proportion of 253 
smokers developed CS-dependency than non-smokers (27.4% versus 20.8%, p<0.0001). 254 
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The cumulative risk of oral CS use at 1,3 and 5 years was 41.1%, 50.9% and 57.5% in smokers, and 255 
34.9%, 43.0% and 49.0% in non-smokers (log rank test for trend, p=0.0001, see Figure 3). 256 
Intestinal surgery 257 
The crude rates for first intestinal surgery in patients with CD were 10.0% and 6.6% in smokers and 258 
non-smokers (p<0.0001). The cumulative risk of first intestinal surgery at 1, 3 and 5 years was 5.3%, 259 
8.5% and 9.3% in smokers and 3.6%, 5.1% and 6.7% in non-smokers at CD diagnosis (log rank test for 260 
trend, p= 0.009, see figure 4). Smoking was associated with a 64% increase in risk of first intestinal 261 
surgery (HR 1.64, 95%CI 1.16-2.52 - see table 3). 262 
Impact of smoking cessation on outcomes in CD 263 
We identified 749 patients who were smokers at CD diagnosis who had subsequent Read codes for 264 
smoking status within the first 2 years following CD diagnosis. Of these, 334 (44%) were classified as 265 
'quitters' and 415 were defined as 'persistent smokers'. 266 
The proportion of female 'persistent smokers' was significantly higher than male patients (66.8% vs 267 
33.2%, p=0.001). There was also significant differences in the proportions of 'persistent smokers' 268 
between the Montreal age groups (A2 50.1%, A3 59.8%, p=0.008). Similarly, 'persistent smokers' 269 
were more likely to have co-existent depression than 'quitters' (19.0% vs 11.6%, p=0.0001). There 270 
were no differences between 'persistent smokers' and 'quitters' with respect to BMI or IMD 271 
categories, or the proportion of patients with co-existent IBS. 272 
'Quitters' had lower overall CS use. Crude oral CS exposure was 53.7% in 'quitters' versus 61.3 in 273 
'persistent smokers' (p=0.03). Mean number of CS flares per year was 0.61 in 'quitters' versus 1.20 in 274 
'persistent smokers', although this difference did not reach statistical significance. However, the 275 
proportion of 'quitters' who maintained steroid-free remission during follow-up was significantly 276 
higher than amongst 'persistent smokers' (45.4% versus 37.5%, p=0.02). Furthermore, there was a 277 
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significantly higher proportion of 'persistent smokers' who developed CS-dependency compared to 278 
the 'quitters' (32.8% in 'persistent smokers' versus 23.9% amongst 'quitters' - see figure 5). 279 
Crude IR rates were 10.2% in 'quitters' and 11.5% in 'persistent smokers (p=0.54). The 1, 3 and 5 year 280 
cumulative risk of IR was 5.6%, 7.9% and 10.3% in 'quitters' and 5.5%, 10.4% and 12.1% in 'persistent 281 
smokers', although the differences did not reach statistical significance (see figure 6). 282 
The marked difference in co-morbid depression prevalence between 'quitters' and 'persistent 283 
smokers' was explored given the potential independent effect of depression on outcomes in IBD.43 In 284 
multiple logistic regression analysis adjusting for age, sex, obesity and social deprivation, depression 285 
was associated with an 84% increased odds of being a 'persistent smoker' (OR 1.84, 95% CI 1.04-286 
3.25, p=0.04). However, amongst our CD cohort, the presence of depression did not impact on the 287 
key outcomes of CS-dependency and intestinal resection (IR) proportionally when comparing 288 
quitters and persistent smokers with/without depression. There were no statistical differences in the 289 
proportion of patients developing CS-dependency between 'persistent smokers' with or without 290 
depression  (35.4% vs.32.5%, p=0.56), or 'quitters' with or without depression (30.8% vs. 23.0%, 291 
p=0.28). Similarly, there were no statistical differences in the proportion of CD patients who 292 
underwent intestinal surgery between 'persistent smokers' with or without depression (17.7% vs. 293 
10.1%, p=0.06), or 'quitters' with or without depression (2.6% vs. 11.2%, p=0.10). 294 




Main findings 297 
This is the is the first population based study to report on the impact of smoking cessation on clinical 298 
outcomes in Crohn’s disease. Smoking at diagnosis was associated with both an increase in CS-299 
requiring flares, the development of CS dependency and risk of intestinal resection. Smoking 300 
cessation within the first 2 years of diagnosis was associated with a reduction in CS-dependency by 301 
almost a quarter compared to persistent smokers. The proportion of quitters in steroid-free 302 
remission during follow-up was almost a fifth higher than in persistent smokers.  Rates of intestinal  303 
surgery amongst quitters were reduced but did not reach statistical significance. 304 
Findings in relationship to other studies 305 
This study is the first to demonstrate the benefit of smoking cessation in a population based cohort 306 
on the key clinical outcome of CS-dependency. In a landmark study by Cosnes et al., CD patients 307 
from a tertiary centre who continued to smoke, when compared to those who had quit or had never 308 
smoked, had higher rates of disease flares, steroid use and immunosuppressant use, although 309 
surgical rates remained unaffected.17 More recently, a prospective observational study by Nunes et 310 
al. including 573 patients with CD from 14 IBD referral centres in Spain reported similar findings.18 311 
Our study is the first to address the impact of smoking on CS-dependency as specifically defined by 312 
ECCO guidelines.44 Reducing CS-dependency is an important goal in IBD management  given the long 313 
term clinical side effects and adverse outcomes associated with CS dependency in IBD.45 Our findings 314 
are in keeping with other referral centre studies that have demonstrated that smoking is associated 315 
with increased corticosteroid use,10,11,12  increased disease activity or disease flares,6,13 and 316 
progression from an inflammatory to a stricturing or penetrating  disease pattern that often requires 317 
surgery.46 A recent meta-analysis that included nine studies of patients with CD, found a 56% 318 
increased risk of disease flare in patients who smoked (pooled odds ratio 1.56, 95%CI 1.21-2.01).16  319 
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We did not find any statistical difference in risk of TP exposure in between smokers and non-320 
smokers, although the results approached statistical significance (35.5% vs. 32.4% in smokers and 321 
non-smokers respectively, p=0.06) Similar findings have also been reported in a study by Seksik et al, 322 
in which immuno-modulator (IM) use did not vary between non-smokers, light smokers and heavy 323 
smokers.6 By contrast, other studies have demonstrated increased IM use amongst smokers with 324 
CD.10,11,12 Interestingly, in a retrospective analysis of steroid-dependent IBD patients, including 103 325 
CD patients treated with thiopurines, there was no difference in steroid-free remission between 326 
smokers and non-smokers.47 327 
We found a significantly higher risk of first intestinal surgery amongst CD patients who smoked at 328 
diagnosis (HR 1.64, 95%CI 1.06-2.52). Our findings add to the body of evidence base that suggest an 329 
increased risk of intestinal surgery amongst smokers.6,9,48 The majority of studies in this field have 330 
been derived from data collected in secondary care. One previous study by Frolkis et al. reported 331 
population-based data on the impact of smoking on risk of surgery in CD using The Health 332 
Improvement Network (THIN), although did not evaluate the impact of smoking cessation in this 333 
cohort. THIN is a UK primary care database that shares information from some practices within CPRD 334 
and also includes patient data from practices that do not contribute to CPRD, although is smaller in 335 
size than CPRD. This study included 1500 CD patients and reported that current smoking at time of 336 
CD diagnosis was associated with a threefold increase in risk of intestinal surgery (HR 2.99, 95%CI 337 
1.52-5.92), although this increased risk was only apparent in patients diagnosed with CD over the 338 
age of 40 years (Montreal A3).3 This contrasts with our own larger study that found no age-related 339 
differences in multi-variate analysis, which may reflect the size of our cohort, differences in adjusting 340 
for confounding, and minor variations in the definitions of smoking at CD diagnosis. 341 
Smoking rates in the UK as in many developed countries have fallen since legislation banning 342 
smoking in public spaces were introduced and our cohorts show similar trends in smoking 343 
prevalence. Data from the Global Burden of Disease (GBD) tobacco collaborators study reported an 344 
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annual percentage drop in smoking prevalence of 0.9-1.2 between 2005-15.2 During our 10 year 345 
study period, there was a sustained and significant decrease in proportion of patients aged 17-40 346 
years (Montreal A2) who were smokers at diagnosis from 37.4% to 30.5%, or a drop of 347 
approximately 0.7%/year. Research on smoking cessation in the UK general population has also 348 
shown a differential rate of smoking cessation, with the highest quit rates amongst 21-30 year olds.49 349 
This is against a background of an overall drop in smoking prevalence in UK adults from 46% in 1974 350 
to 19% in 2014.50 The drop in smokers at diagnosis may also reflect changing smoking habits in the 351 
wake of the UK smoking ban that was introduced in July 2007,51 in addition to the introduction of 352 
Quality and Outcome Framework (QOF) targets in UK general practices.28 In a sensitivity analysis of 353 
our own data, we found the proportion of CD patients aged 17-40 years (Montreal A2) who smoked 354 
at diagnosis dropped significantly from 37% in the pre-smoking ban era to 30% in the post-smoking 355 
ban era, whereas there were no changes in the other age categories. 356 
That smoking worsens, and conversely cessation improves disease course in CD, can be explained by 357 
a host of biological, clinical and social factors. Tobacco smoke is postulated to cause inflammation 358 
and damage to the gastrointestinal tract via a number of mechanisms.52 Smoking may lead to 359 
alterations in the intestinal flora in patients with IBD manifest as decreased species diversity and 360 
reduced anti-inflammatory phyla, for example Firmicutes.53 Smoking in CD may also increase 361 
potentially pro-inflammatory Bacteioroides species.54 Constituents of tobacco smoke may inhibit 362 
anti-inflammatory pathways, dysregulate monocyte function and alter small bowel 363 
permeability.55,56,57 364 
Smoking may also impact on the efficacy of CD-specific medication. Smokers are more likely to 365 
discontinue thiopurine therapy because of side effects.47 Smoking has also been suggested to reduce 366 
the effectiveness of biologic therapies, but this association remains unconfirmed.58 Furthermore, 367 




Strengths and limitations 370 
This is the first population-based study investigating the impact of smoking cessation on disease 371 
outcomes in patients with Crohn's disease. Data were drawn from a large nationally representative 372 
validated research database free of referral centre bias. CPRD has previously been validated as a tool 373 
to study IBD, including smoking exposure.20,60 Completeness for the recording of smoking status is 374 
reported at over 98% in some patient populations.28 In our regression model we have accounted for 375 
multiple demographic and clinical covariates that add strength to our findings.  376 
We acknowledge certain limitations to our study. A potential limitation is that longitudinal data with 377 
regard to smoking continuation and cessation was incomplete and reduced the size of the cohort 378 
available for analysis of the impact of smoking cessation. However to date this is the only population 379 
based study to evaluate the impact of smoking cessation in CD. Furthermore, our measure of 380 
smoking status may have been subject to recall bias by patients or a failure of clinicians to inquire 381 
about and record status acurately.4 This could potentially result in an underestimation of any effect.  382 
Furthermore, our study did not account for smoking intensity or alternative types of tobacco 383 
exposure.  384 
With respect to the smoking cessation analysis, we evaluated the impact of cessation with in the first 385 
2 years of diagnosis. We classified the status of quitting or smoking persistence based on changes in 386 
smoking codes within the first two years after CD diagnosis. Our methodology defines cessation 387 
based on an event documented and coded for by the primary care physician and not the actual date 388 
the patient stopped smoking. It is possible therefore that  CS use and IR may have occurred before 389 
the actual 'quit date'. Reassuringly in this respect we found in a sensitivity analysis that mean time to 390 
a change in smoking code (227 days from CD diagnosis) was significantly shorter than the mean time 391 
to either CS dependency (1112 days) or intestinal surgery (395 days)  This suggests smoking 392 
cessation usually preceded CS use or IR in our analysis . 393 
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We also acknowledge CPRD contains limited information about disease phenotype, activity, severity 394 
and endoscopic data, but emphasize that this database has been validated for use in IBD-related 395 
research.20 We have however attempted to adjust for some of these restrictions including 396 
developing surrogate markers for disease activity to generate 'CS-flare' data using a previously 397 
published methodology.35 We also recognise the potential limitations of using CS prescription data 398 
to define disease activity rather than objective markers. Nevertheless this does often reflect ‘real 399 
world’ clinical practice. Our methodology will also fail to capture patients who choose against taking 400 
steroids for a flare, although postulate this would be a small proportion of patients. 401 
We were however able to control for disease severity using the validated Beaugerie index.42 402 
Additionally, we used a previously described comprehensive list of Read codes to determine 403 
whether a patient had had intestinal surgery.29 We accept some patients, in particular those in the 404 
older (A3) age group, may have undergone surgery for indications other than CD, such as cancer. The 405 
associated impact of smoking status on IBD-specific hospitalisation would also have been of interest 406 
but CPRD does not code for this parameter. 407 
CPRD contains limited data on anti-tumour necrosis factor (aTNF) medications, since these 408 
treatments are usually prescribed in secondary care and thus is a potential confounder. It is 409 
noteworthy that in 2006, only an estimated 3% of the British CD population was on biologic 410 
therapy,61 but has steadily risen since.62 In our multivariate analysis we have shown that era of 411 
diagnosis was not a significant covariate implying that changes in biologic use between the era did 412 
not impact significantly on the measured outcomes. This is also consistent with a recent  Spanish 413 
registry study, which reported that smoking was associated with a more deleterious disease course 414 
irrespective of increased biologic use.11 415 
Implications 416 
Our results support the hypothesis that intestinal inflammation is exacerbated by tobacco exposure 417 
in Crohn’s disease and worsens subsequent clinical outcomes, notably steroid use and requirement 418 
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for intestinal surgery. Importantly it supports the notion that smoking cessation has a favourable 419 
impact. 420 
Smoking is the only truly modifiable risk factor in disease course in CD and our findings underscore 421 
the importance of assessing smoking status at first presentation, and counselling patients who 422 
smoke that continued tobacco use is likely to be associated with detrimental outcomes, but that 423 
quitting smoking will improve their disease course. This is particularly pertinent given patient 424 
knowledge as to the potentially negative impact of smoking on outcomes in IBD may be lacking.63,64 425 
We recommend that smoking cessation strategies should be prioritised in systematic shared care 426 
protocols bridging primary and secondary care since there is good evidence, that when clinicians 427 
support patients, about a third will quit,65 with resultant improvement in clinical outcomes in those 428 
that achieve this goal.18 There may be added value in focusing this effort on certain target 429 
populations including younger patients or light smokers who are more likely to succeed with 430 
complete cessation.66 There may also be considerable economic benefits to healthcare services 431 
employing cessation programs in CD.67 432 
Further work is needed to quantify the effect of smoking exposure ideally using objective markers 433 
that are not subject to recall bias such as salivary cotinine.68 Additionally, future prospective studies 434 
that quantify smoking exposure by accurately recording smoking intensity (number of cigarettes 435 
smoked per day), could be used to investigate the potential of a tobacco 'dose effect'.  436 
Conclusions 437 
Amongst patients with CD, smoking status at diagnosis impacts on key clinical outcomes within the 438 
first five years of the disease course. CD patients who are smokers at diagnosis are a third more 439 
likely to be steroid dependent, have more steroid flares during follow-up, and are two thirds more 440 
likely to undergo intestinal surgery. Patients who stopped smoking within the first 2 years following 441 
CD diagnosis had reduced rates of CS-dependency, a key clinical outcome in this cohort. These 442 
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findings underpin the importance of early targeted smoking cessation programmes within this 443 
patient group. 444 
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Table and figure legends 656 
Figure 1: 657 
IBD - inflammatory bowel disease 658 
CPRD - Clinical Practice Research Datalink 659 
UTS - Up to Standard 660 
QOF - UK Quality Outcomes and Framework introduced to GPs in 2004 661 
UC - Ulcerative Colitis 662 
CD - Crohn's disease 663 
 664 
Figure 2: 665 
Bar height indicate % of smokers at CD diagnosis by each age category. Actual number of smokers in each 666 
group displayed in base of individual bars. 667 
* p=0.02 for across era comparison for proportion of smokers at CD diagnosis in Montreal A2 category. No 668 
significant differences in A1 or A3 categories across era. Note in Era 1 and Era 5, there were no smokers in the 669 
A1 group. 670 
Era 1: 2005-06 (inclusive), Era 2: 2007-08, Era 3: 2009-10, Era 4: 2001-12, Era 5: 2013-14 671 
A1 - age at diagnosis <17 years 672 
A2 - age at diagnosis 17-40 years 673 
A3 - age at diagnosis >40 years 674 
 675 
Figure 3: 676 
CS - corticosteroid   IBD - inflammatory bowel disease   CD - Crohn's disease 677 
Figure 4: 678 




Table 1: 681 
a - Age at diagnosis categories as per Montreal classification (A1 <17 years, A2 17-40, A3 >40 years) 682 
b - BMI (Body Mass index) - calculated as the closest BMI recording within one year of Crohn's diagnosis. Data available for 683 
58% of patients 684 
c - IMD (Index of Multiple Deprivation) 685 
d - IBS (Irritable Bowel Syndrome) - co-diagnosis considered as any patient with a defined Read code for IBS in records 686 
e - Co-diagnosis of depression considered if patient had any Read code for depressive illness in CPRD record 687 
f - BI (Beaugerie index) - BI score of 2 or more associated with disabling disease course. Please see methodology for 688 
detailed description of the indices 689 
 690 
Table 2: 691 
* a steroid flare was considered as the first steroid prescription (after a Crohn's diagnosis) and any other 692 
prescription for oral steroids following a 4 month time free of steroid prescription 693 
** steroid dependency calculated as any patient with a repeat steroid prescription within 3 months of the end 694 
of a previous steroid prescription or patients with steroid prescriptions for greater than 3 months 695 
 696 
Table 3: 697 
Multivariate analysis includes all covariates of univariate analysis. Only significant hazard ratios shown for multivariate 698 
analysis 699 
HR - Hazard ratio   CI - Confidence Interval   IBD - Inflammatory Bowel Disease  BMI - Body Mass Index   IMD - index of 700 
multiple depravity   IBS - irritable bowel syndrome   5-ASA - 5-aminosalicylates   TP - Thiopurine   BI -  Beaugerie Index  701 
a - smoker at diagnosis defined as any patient with Read codes for active smoking within the year preceding IBD diagnosis 702 
b - Age categories as per Montreal classification (A1 <17 years, A2 17-40, A3 >40 years) 703 
c - Era 1: 2005-06 (inclusive), Era 2: 2007-08, Era 3: 2009-10, Era 4: 2011-12, Era 5: 2013-14 704 
d - calculated as the closest recorded BMI to date of IBD diagnosis, one year either side of IBD diagnosis 705 
e - IMD upper includes IMD categories 1 and 2 (versus IMD category 3,4 and 5) 706 
f - IBS co-diagnosis defined as any patient with a Read code for IBS before or after IBD diagnosis. Depression defined as any 707 
patient with a Read code for depression before or after IBD diagnosis 708 
g - exposure of 5-ASA or TP medications defined as any patients with at least one or more prescription for either 5-ASA of 709 
TP after IBD diagnosis 710 
h - BI 2+ - Beaugerie Index score of 2+  -  please refer to methodology for exact details of these definitions 711 




Figure 1: schematic of  cohort construction for incident cases of Crohn's disease 714 
 715 
IBD - inflammatory bowel disease 716 
CPRD - Clinical Practice Research Datalink 717 
UTS - Up to Standard 718 
QOF - UK Quality Outcomes and Framework introduced to GPs in 2004 719 
UC - Ulcerative Colitis 720 
CD - Crohn's disease 721 
  722 
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Figure 2: Smoking prevalence at diagnosis of CD patients by Montreal age category and year of CD 723 
diagnosis 724 
 725 
Bar height indicate % of smokers at CD diagnosis by each age category. Actual number of smokers in each 726 
group displayed in base of individual bars. 727 
* p=0.02 for across era comparison for proportion of smokers at CD diagnosis in Montreal A2 category. No 728 
significant differences in A1 or A3 categories across era.. Note in Era 1 and Era 5, there were no smokers in the 729 
A1 group. 730 
Era 1: 2005-06 (inclusive), Era 2: 2007-08, Era 3: 2009-10, Era 4: 2001-12, Era 5: 2013-14 731 
A1 - age at diagnosis <17 years 732 
A2 - age at diagnosis 17-40 years 733 
A3 - age at diagnosis >40 years 734 
  735 






































































Figure 3: KM curves showing probability of oral CS exposure in patients with Crohn's disease given 736 
diagnosis smoking status 737 
 738 
CS - corticosteroid   IBD - inflammatory bowel disease   CD - Crohn's disease 739 
  740 
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Figure 4: KM curves showing probability of first intestinal surgery in patients with Crohn's disease 741 
given diagnosis smoking status 742 
 743 
IBD - inflammatory bowel disease   CD - Crohn's disease 744 
  745 
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Figure 5: Bar chart comparing CS-dependency between quitters and persistent smokers amongst 746 
patients with CD  747 
 748 
legend: 749 
Quitters  - CD patients who were smokers at diagnosis but had subsequent Read codes in the two years 750 
following diagnosis indicating they were ex or non-smokers 751 
Persistent smokers - CD patients who were smokers at diagnosis and had subsequent Read codes in the two 752 
years following diagnosis indicating they were still smokers 753 
  754 
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Figure 6: KM curves showing probability of first intestinal surgery in patients with Crohn's disease: 755 
'quitters' versus 'persistent smokers'  756 
  757 
legend: 758 
Quitters  - CD patients who were smokers at diagnosis but had subsequent Read codes in the two years 759 
following diagnosis indicating they were ex or non-smokers 760 
Persistent smokers - CD patients who were smokers at diagnosis and had subsequent Read codes in the two 761 
years following diagnosis indicating they were still smokers 762 





Table 1: baseline characteristics of cohort 766 
 Smoker at Crohn's 
diagnosis 
(n=1121) 












Age at diagnosisa (%) 
    A1 
    A2 













BMI category at 
diagnosisb (%) 
   Underweight 
   Normal 
   Overweight 



















Social deprivationc (%) 
   IMD 1 
   IMD 2 
   IMD 3 
   IMD 4 




















   IBSd 










Severity indicesf (%) 
   BI score     0 
                               1 
                      2 














a - Age at diagnosis categories as per Montreal classification (A1 <17 years, A2 17-40, A3 >40 years) 767 
b - BMI (Body Mass index) - calculated as the closest BMI recording within one year of Crohn's diagnosis. Data available for 768 
58% of patients 769 
c - IMD (Index of Multiple Deprivation) 770 
d - IBS (Irritable Bowel Syndrome) - co-diagnosis considered as any patient with a defined Read code for IBS in records 771 
e - Co-diagnosis of depression considered if patient had any Read code for depressive illness in CPRD record 772 
f - BI (Beaugerie index) - BI score of 2 or more associated with disabling disease course. Please see methodology for 773 





Table 2: Steroid flares and steroid dependency in patients with Crohn's disease by smoking status 777 
at diagnosis 778 






    0 
    0-1 






















* a steroid flare was considered as the first steroid prescription (after a Crohn's diagnosis) and any other 780 
prescription for oral steroids following a 4 month time free of steroid prescription 781 
** steroid dependency calculated as any patient with a repeat steroid prescription within 3 months of the end 782 
of a previous steroid prescription or patients with steroid prescriptions for greater than 3 months 783 
  784 
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Table 3: Univariate and multivariate Cox regression analysis for risk of intestinal surgery in 786 
patients with Crohn's disease 787 




HR 95% CI p value HR 95% CI p value 
Smoking status 
at diagnosisa 

































Age at IBD 
diagnosisb 
   A1 
   A2 































Era of IBD 
diagnosisc 
   Era 1 
   Era 2 
   Era 3 
   Era 4 












































   Underweight 
   Normal 
   Overweight 





















































   IBS 




















   5-ASA 

































Multivariate analysis includes all covariates of univariate analysis. Only significant hazard ratios shown for multivariate 788 
analysis 789 
HR - Hazard ratio   CI - Confidence Interval   IBD - Inflammatory Bowel Disease  BMI - Body Mass Index   IMD - index of 790 
multiple depravity   IBS - irritable bowel syndrome   5-ASA - 5-aminosalicylates   TP - Thiopurine   BI -  Beaugerie Index  791 
a - smoker at diagnosis defined as any patient with Read codes for active smoking within the year preceding IBD diagnosis 792 
b - Age categories as per Montreal classification (A1 <17 years, A2 17-40, A3 >40 years) 793 
c - Era 1: 2005-06 (inclusive), Era 2: 2007-08, Era 3: 2009-10, Era 4: 2011-12, Era 5: 2013-14 794 
40 
 
d - calculated as the closest recorded BMI to date of IBD diagnosis, one year either side of IBD diagnosis 795 
e - IMD upper includes IMD categories 1 and 2 (versus IMD category 3,4 and 5) 796 
f - IBS co-diagnosis defined as any patient with a Read code for IBS before or after IBD diagnosis. Depression defined as any 797 
patient with a Read code for depression before or after IBD diagnosis 798 
g - exposure of 5-ASA or TP medications defined as any patients with at least one or more prescription for either 5-ASA of 799 
TP after IBD diagnosis 800 
h - BI 2+ - Beaugerie Index score of 2+  -  please refer to methodology for exact details of these definitions 801 
 802 
